Skip to main content

Guyer Charles Greg's Form 4 filing

Biomarin Pharmaceutical IncBMRN · filed Mar 7, 2025

Accession no.
0001048477-25-000025
Filed
Mar 7, 2025
Trade date
Mar 6, 2025
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction. Open-market sales total $501.4K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Guyer Charles GregCIK 0001811096Officer (EVP, Chief Technical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 6, 2025Common StockSSaleDisposed−7,034$71.28F1−$501,383.5287,655Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price in column 4 is the weighted average price. The price actually received ranged from $71.276 to $71.285. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)